Does big pharma dominate the coronavirus vaccine race? It might seem that way. Of the five COVID-19 vaccine candidates in late-stage testing that could be players in the U.S. market, three are being developed or co-developed by huge drugmakers.
But that still leaves a couple of not-so-big companies in the mix. Moderna and Novavax are clinical-stage biotechs that just might emerge as tremendous winners in the COVID-19 vaccine market. Here’s how they stack up against each other from an investment perspective.
Coronavirus programs
Moderna definitely enjoys something of a head start over Novavax in this race. While Novavax has a phase 3 clinical study for its experimental COVID-19 vaccine NVX-CoV2373 underway in the U.K., it hasn’t begun a pivotal U.S. study yet.
